Phenotyping Cardiogenic Shock.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
20 07 2021
Historique:
pubmed: 7 7 2021
medline: 30 10 2021
entrez: 6 7 2021
Statut: ppublish

Résumé

Background Cardiogenic shock (CS) is a heterogeneous syndrome with varied presentations and outcomes. We used a machine learning approach to test the hypothesis that patients with CS have distinct phenotypes at presentation, which are associated with unique clinical profiles and in-hospital mortality. Methods and Results We analyzed data from 1959 patients with CS from 2 international cohorts: CSWG (Cardiogenic Shock Working Group Registry) (myocardial infarction [CSWG-MI; n=410] and acute-on-chronic heart failure [CSWG-HF; n=480]) and the DRR (Danish Retroshock MI Registry) (n=1069). Clusters of patients with CS were identified in CSWG-MI using the consensus k means algorithm and subsequently validated in CSWG-HF and DRR. Patients in each phenotype were further categorized by their Society of Cardiovascular Angiography and Interventions staging. The machine learning algorithms revealed 3 distinct clusters in CS: "non-congested (I)", "cardiorenal (II)," and "cardiometabolic (III)" shock. Among the 3 cohorts (CSWG-MI versus DDR versus CSWG-HF), in-hospital mortality was 21% versus 28% versus 10%, 45% versus 40% versus 32%, and 55% versus 56% versus 52% for clusters I, II, and III, respectively. The "cardiometabolic shock" cluster had the highest risk of developing stage D or E shock as well as in-hospital mortality among the phenotypes, regardless of cause. Despite baseline differences, each cluster showed reproducible demographic, metabolic, and hemodynamic profiles across the 3 cohorts. Conclusions Using machine learning, we identified and validated 3 distinct CS phenotypes, with specific and reproducible associations with mortality. These phenotypes may allow for targeted patient enrollment in clinical trials and foster development of tailored treatment strategies in subsets of patients with CS.

Identifiants

pubmed: 34227396
doi: 10.1161/JAHA.120.020085
pmc: PMC8483502
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e020085

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL139785
Pays : United States

Références

Eur Heart J. 2017 Dec 14;38(47):3523-3531
pubmed: 29020341
Circ Cardiovasc Qual Outcomes. 2016 Mar;9(2):117-25
pubmed: 26884615
Eur J Heart Fail. 2015 May;17(5):501-9
pubmed: 25820680
Bioinformatics. 2010 Jun 15;26(12):1572-3
pubmed: 20427518
Eur Heart J. 2014 Jan;35(3):156-67
pubmed: 24014384
Lancet Diabetes Endocrinol. 2019 Sep;7(9):684-694
pubmed: 31345776
Eur J Heart Fail. 2019 Nov;21(11):1370-1378
pubmed: 31339222
IEEE Trans Pattern Anal Mach Intell. 1979 Mar;1(3):306-7
pubmed: 21868861
J Am Coll Cardiol. 2017 Apr 18;69(15):1913-1920
pubmed: 28408020
JAMA. 2019 May 28;321(20):2003-2017
pubmed: 31104070
J Heart Lung Transplant. 2009 Jun;28(6):535-41
pubmed: 19481012
Circulation. 2018 Nov 13;138(20):2298-2300
pubmed: 30571518
J Am Coll Cardiol. 2019 Oct 29;74(17):2129-2131
pubmed: 31548098
Circulation. 2015 Jan 20;131(3):232-3
pubmed: 25601948
Circulation. 2015 Jan 20;131(3):269-79
pubmed: 25398313
Catheter Cardiovasc Interv. 2019 Jul 1;94(1):29-37
pubmed: 31104355
N Engl J Med. 1999 Aug 26;341(9):625-34
pubmed: 10460813
Am J Epidemiol. 2014 Mar 15;179(6):764-74
pubmed: 24589914
Bioinformatics. 2012 Jan 1;28(1):112-8
pubmed: 22039212
Eur Heart J. 2019 Aug 21;40(32):2671-2683
pubmed: 31274157
Am J Cardiol. 1967 Oct;20(4):457-64
pubmed: 6059183
Circulation. 2017 Oct 17;136(16):e232-e268
pubmed: 28923988
Circ Heart Fail. 2020 Sep;13(9):e007099
pubmed: 32900234
N Engl J Med. 1979 Jun 14;300(24):1350-8
pubmed: 440357
Lancet Diabetes Endocrinol. 2018 May;6(5):361-369
pubmed: 29503172
J Am Coll Cardiol. 2019 Oct 29;74(17):2117-2128
pubmed: 31548097
J Am Heart Assoc. 2014 Jan 13;3(1):e000590
pubmed: 24419737

Auteurs

Elric Zweck (E)

The CardioVascular Center Tufts Medical Center Boston MA.
Medical Faculty Heinrich Heine University Düsseldorf Germany.

Katherine L Thayer (KL)

The CardioVascular Center Tufts Medical Center Boston MA.

Ole K L Helgestad (OKL)

Department of Cardiology Odense University Hospital Odense Denmark.
Odense Patient Data Explorative Network University of Southern Denmark Odense Denmark.

Manreet Kanwar (M)

Department of Cardiovascular Medicine Allegheny Health Network Pittsburgh PA.

Mohyee Ayouty (M)

Tufts University School of Medicine Boston MA.

A Reshad Garan (AR)

Beth Israel Deaconess Medical Center Boston MA.

Jaime Hernandez-Montfort (J)

Cleveland Clinic Florida Weston FL.

Claudius Mahr (C)

University of Washington Medical Center Seattle WA.

Detlef Wencker (D)

Baylor Scott & White Advanced Heart Failure Clinic Dallas TX.

Shashank S Sinha (SS)

Inova Heart and Vascular Institute Falls Church VA.

Esther Vorovich (E)

Northwestern Medicine Chicago IL.

Jacob Abraham (J)

Providence Heart Institute Portland OR.

William O'Neill (W)

Henry Ford Hospital Detroit MI.

Song Li (S)

University of Washington Medical Center Seattle WA.

Gavin W Hickey (GW)

UPMC Heart and Vascular Institute Pittsburgh PA.

Jakob Josiassen (J)

Department of Cardiology Rigshospitalet Copenhagen Denmark.

Christian Hassager (C)

Department of Cardiology Rigshospitalet Copenhagen Denmark.
Department of Clinical Medicine University of Copenhagen Denmark.

Lisette O Jensen (LO)

Department of Cardiology Odense University Hospital Odense Denmark.

Lene Holmvang (L)

Department of Cardiology Rigshospitalet Copenhagen Denmark.
Department of Clinical Medicine University of Copenhagen Denmark.

Henrik Schmidt (H)

Department of Cardiothoracic Anesthesia Odense University Hospital Odense Denmark.

Hanne B Ravn (HB)

Department of Clinical Medicine University of Copenhagen Denmark.
Department of Cardiac Anesthesiology Rigshospitalet Copenhagen Denmark.

Jacob E Møller (JE)

Department of Cardiology Odense University Hospital Odense Denmark.
Odense Patient Data Explorative Network University of Southern Denmark Odense Denmark.

Daniel Burkhoff (D)

Cardiovascular Research Foundation New York NY.

Navin K Kapur (NK)

The CardioVascular Center Tufts Medical Center Boston MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH